
Sign up to save your podcasts
Or


In this episode, Bernie and Anthony are joined by the Myeloma Man Dr. Manni Mohyuddin and lymphoma expert Dr. David Russler-Germain to discuss the very recent ODAC decisions on the STARGLO (glofitamab + GemOx) and AQUILA (daratumumab for smoldering multiple myeloma) trials. Did ODAC do their due diligence, or are there double standards? There is a lot to unpack in this episode!
By Bernard Marini, Anthony Perissinotti, et al.4.5
2828 ratings
In this episode, Bernie and Anthony are joined by the Myeloma Man Dr. Manni Mohyuddin and lymphoma expert Dr. David Russler-Germain to discuss the very recent ODAC decisions on the STARGLO (glofitamab + GemOx) and AQUILA (daratumumab for smoldering multiple myeloma) trials. Did ODAC do their due diligence, or are there double standards? There is a lot to unpack in this episode!

499 Listeners

28 Listeners

188 Listeners

8,780 Listeners

2 Listeners

755 Listeners

12 Listeners

52 Listeners

60 Listeners

136 Listeners

1 Listeners

48 Listeners

190 Listeners

42 Listeners

4 Listeners